Article

Glaucoma technology-driven adherence program to be tested

A clinical trial will be conducted by Johns Hopkins University's Wilmer Eye Institute on patient adherence and clinical outcomes for people with glaucoma using technology (Memotext).

Bethesda, MD-A clinical trial will be conducted by Johns Hopkins University’s Wilmer Eye Institute on patient adherence and clinical outcomes for people with glaucoma using technology (Memotext).

The Impact of Automated Dosing Reminders on Medication Adherence Using HealthVault will be a 14-month, 500-patient study to be led by Michael V. Boland, MD, PhD, of the Wilmer Eye Institute. The study will use telephone calls and text messages in an effort to improve patient outcomes by improving medication adherence.

"We believe this new interface will significantly improve medication adherence in patients with glaucoma," said Amos Adler, president of Memotext. "It is an honor to collaborate on this special grant, and we are confident this trial will demonstrate that Memotext's technology-driven adherence solutions can make a significant difference in the lives of patients managing various conditions."

Studies have shown that medication non-adherence costs North America more than $100 billion and 125,000 lives every year. Research also shows that 70% of prescriptions are not consumed and 20% of new drug prescriptions are not filled for the first time.

Approximately 40% of patients with glaucoma have difficulty taking their eye drops on a regular basis, resulting in poor care despite an appropriate physician diagnosis and treatment plan.

"Adherence to glaucoma therapy is one of the largest barriers we face in achieving therapeutic success," said glaucoma specialist Donald Budenz, MD, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami. "We have numerous effective medications to treat this disease, but if patients don't use them, they're not effective. Providing real-time reminders to improve adherence to therapy will be a major step forward in the treatment of chronic diseases such as glaucoma."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.